Sarah A. Tomkowiak

Washington, D.C.
  • 555 Eleventh Street, NW
  • Suite 1000
  • Washington, D.C. 20004-1304
  • USA
 
 

Sarah Tomkowiak represents issuers as well as their officers and directors in complex business litigation and investigations, including securities class actions, merger litigation, and enforcement actions.

Ms. Tomkowiak represents clients active in numerous industries in:

  • Securities fraud class actions
  • Shareholder derivative litigation
  • Mergers and acquisitions litigation
  • Internal investigations
  • Securities and Exchange Commission (SEC) investigations
  • Corporate governance

She draws on extensive experience in all aspects of civil litigation, including first-chair and federal jury trial experience, as well as with Section 10(b) and Section 11 of the federal securities laws.

She conducts internal investigations into financial reporting, accounting, disclosures, and internal controls issues, and advises clients on a range of matters, including corporate governance and the securities laws.

Ms. Tomkowiak has been recognized as a Rising Star in Washington, D.C. Super Lawyers lists 2014-2017, and as a Law360 Rising Star in 2019.

Leadership

Ms. Tomkowiak is a founding member of Washington Area Women Trial Attorneys (WAWTA). She is also active in the D.C. Women’s Bar Association and is Vice Chair of the ABA’s Class and Derivative Actions Subcommittee. She co-authors the ABA’s annual publication Recent Developments in Business and Corporate Litigation - Class Actions.

Ms. Tomkowiak participates in firm management, currently serving on the Recruiting Committee, and previously on the Associates and Pro Bono Committees.


Ms. Tomkowiak’s recent representations include:

  • Puma Biotechnology and officers in a federal securities class action in the Central District of California. The jury reached a unanimous verdict in Puma’s favor on the majority of plaintiffs’ claims, awarding a miniscule damages amount in the first federal securities class action to reach a verdict in nearly a decade.
  • Sinovac Biotech in a shareholder activism related litigation in the District of Massachusetts, challenging disclosures relating to change of control intent.
  • Wal-Mart Stores and officers, in two high-profile federal securities class actions in the Southern District of New York and Western District of Arkansas, challenging disclosures relating to an FCPA investigation.
  • Checkpoint Systems, a manufacturer of retail anti-theft systems, and officers, in a class action in the District of New Jersey, over the company’s restatement of its tax accounting expense in 2015.
  • Weatherford International and officers, in federal securities class actions in the Southern District of New York, derivative litigation, and an SEC investigation arising out of financial restatements related to income tax accounting.
  • HCA, the largest US for-profit hospital chain, in a Section 11 securities class action in the Middle District of Tennessee, challenging disclosures in the offering materials for its 2011 initial public offering.
  • Booz Allen, a consulting services firm, and officers in a federal securities fraud jury trial in the Southern District of New York.
  • K12, an online education company, and individual officers, in a federal securities class action in Eastern District of Virginia.
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.